Statin therapy cost-effectively improves health outcomes for ≥70s
By
HealthDay News
Sep 12, 2024
The lifetime use of a standard statin increased quality-adjusted life years by 0.24 to 0.70, with further increase seen for higher-intensity statins.
Semaglutide reduces risk for MACE in patients with obesity and heart failure
By
Haymarket Media
Aug 28, 2024
MACE, heart failure composite end point, cardiovascular death and all-cause death all improved with semaglutide for patients with versus without heart failure.